Sunbird Bio’s blood test to indirectly detect toxic clumps of alpha-synuclein protein in the brain, a hallmark of Parkinson’s disease, may help yield an accurate Parkinson’s diagnosis, according to data from a clinical study. The company presented the results in a poster, “Using neural derived EV-bound biomarkers in…
Delphi-MD, a system that measures brain activity, may be used for the early diagnosis of Parkinson’s disease and for differentiating between its subtypes, particularly those marked by rapid disease progression, a study shows. The technology, developed by Quantalx Neuroscience, provides direct, real-time imaging of the brain’s electrical…
SandboxAQ has signed a $25 million research grant through an initiative of The Michael J. Fox Foundation for Parkinson’s Research (MJFF) to develop new treatments that target the LRRK2 gene, mutations in which are one of the most common genetic causes of Parkinson’s disease. Under the partnership, which…
Besides motor challenges, people with Parkinson’s disease have difficulty with motor imagery, or generating a mental representation of a movement, a study showed. That’s particularly true for the more affected side of the body. “Even when people with Parkinson’s think about movement, it’s different for their more affected side,”…
A new partnership will work to develop customized assays to detect and quantify blood biomarkers to support the advancement of new treatments for neurodegenerative diseases, including Parkinson’s disease. Adx Neurosciences, which makes biomarker assays for neurodegenerative diseases, and Alamar Biosciences, a proteomics company with technology to detect…
Hearing loss may be a risk factor for later developing Parkinson’s disease, and the risk may be higher for people with more severe impairment, according to a recent study of U.S. military veterans data. However, the use of hearing aids within two years after the diagnosis of hearing difficulties…
The Michael J. Fox Foundation for Parkinson’s Research (MJFF) announced an initiative to accelerate the identification of biomarkers and the development of new therapies targeting the LRRK2 gene, one of the most common causes of inherited Parkinson’s disease. The program, LRRK2 Investigative Therapeutics Exchange, or LITE, provides “tens…
The American Parkinson Disease Association (APDA) is funding a new APDA Center for Advanced Research at Yale University’s School of Medicine, the newest of nine such centers in its U.S. network, in recognition of the school’s work into the causes and the potential for personalized treatment of Parkinson’s…
Booster Therapeutics announced its launch and the start of work into therapeutics that improve the body’s ability to clear itself of the defective, disease-causing proteins that drive Parkinson’s disease and other neurodegenerative conditions. The company, which is based in Berlin and whose opening was supported by $15 million…
The Michael J. Fox Foundation for Parkinson’s Research (MJFF) has awarded a second research grant of $2.5 million to Selonterra to advance the California-based company’s preclinical development of new therapeutic compounds targeting the genetic causes of Parkinson’s disease. Selonterra specifically will be testing whether compounds that…
Get regular updates to your inbox.
